0000000000615042

AUTHOR

Guru Sonpavde

showing 3 related works from this author

Modified Glasgow Prognostic Score is Associated With Risk of Recurrence in Bladder Cancer Patients After Radical Cystectomy

2015

Recently, many studies explored the role of inflammation parameters in the prognosis of urinary cancers, but the results were not consistent. The modified Glasgow Prognostic Score (mGPS), a systemic inflammation marker, is a prognostic marker in various types of cancers. The aim of the present study was to investigate the usefulness of the preoperative mGPS as predictor of recurrence-free (RFS), overall (OS), and cancer-specific (CSS) survivals in a large cohort of urothelial bladder cancer (UBC) patients.A total of 1037 patients with UBC were included in this study with a median follow-up of 22 months (range 3-60 months). An mGPS = 0 was observed in 646 patients (62.3%), mGPS = 1 in 297 pa…

to-lymphocyte ratioAdultMaleRiskmedicine.medical_specialtyPrognosimedicine.medical_treatmentCystectomyGastroenterologySettore MED/24 - UrologiaCystectomyMedicine (all); c-reactive protein; advanced urothelial carcinoma; to-lymphocyte ratioc-reactive proteinRetrospective StudieInternal medicine80 and overHumansMedicineStage (cooking)advanced urothelial carcinomaRetrospective StudiesAgedAged 80 and overModified Glasgow Prognostic Score is Associated With Risk of Recurrence in Bladder Cancer Patients After Radical Cystectomy: A Multicenter Experience.Univariate analysisBladder cancerbusiness.industryProportional hazards modelMedicine (all)Hazard ratioBladder cancer Radical cystectomyRetrospective cohort studyGeneral MedicineMiddle AgedPrognosismedicine.diseaseSurgeryNeoplasm RecurrenceLocalUrinary Bladder NeoplasmsUrinary Bladder NeoplasmCohortFemaleNeoplasm Recurrence LocalAdult; Aged; Aged 80 and over; Female; Humans; Male; Middle Aged; Neoplasm Recurrence Local; Prognosis; Retrospective Studies; Risk; Urinary Bladder Neoplasms; Cystectomy; Medicine (all)businessHumanMedicine
researchProduct

RANDOMIZED PHASE II STUDY OF FIRST-LINE EVEROLIMUS (EVE) + BEVACIZUMAB (BEV) VERSUS INTERFERON ALFA-2A (IFN) + BEV IN PATIENTS (PTS) WITH METASTATIC …

2012

ABSTRACT Background Study results demonstrated that IFN augments BEV activity and improves median PFS in pts with mRCC. Thus, combination BEV + IFN is a standard first-line treatment option for mRCC. Combining BEV with the mTOR inhibitor EVE may be an efficacious and well-tolerated treatment option. The open-label, phase II RECORD-2 trial compared first-line EVE + BEV and IFN + BEV in mRCC. Patients and methods: Therapy-naive pts with clear cell mRCC and prior nephrectomy were randomized 1:1 to BEV 10 mg/kg IV every 2 weeks with either EVE 10 mg oral daily or IFN (9 MIU SC 3 times/week, if tolerated). Tumour assessments were every 12 weeks. Primary objective was treatment effect on progress…

medicine.medical_specialtymedicine.medical_treatmentGastroenterology03 medical and health sciences0302 clinical medicineProstateInternal medicinemedicineStomatitisObjective response030304 developmental biology0303 health sciencesProteinuriaGenitourinary systembusiness.industryTreatment optionsHematologymedicine.diseaseNephrectomy3. Good healthmedicine.anatomical_structureOncologyTolerability030220 oncology & carcinogenesismedicine.symptombusinessAnnals of Oncology
researchProduct

Type 2 diabetes mellitus predicts worse outcomes in patients with high-grade T1 bladder cancer receiving bacillus Calmette-Guérin after transurethral…

2020

Objectives: The aim of this multicenter study was to investigate the prognostic role of type 2 diabetes mellitus (T2DM) comorbidity in a large multi-institutional cohort of patients with primary T1HG/G3 non–muscle-invasive bladder cancer (NMIBC) treated with transurethral resection of the bladder (TURB). Materials and methods: A total of 1,172 patients with primary T1 HG/G3 who had NMIBC on re-TURB and who received adjuvant intravesical bacillus Calmette-Guérin therapy with maintenance were included. Endpoints were recurrence-free survival and progression-free survival. Results: A total of 231 (19.7%) of patients had T2DM prior to TURB. Five-year recurrence-free survival estimates were 12.5…

Malemedicine.medical_specialtyDiabetes mellituUrologymedicine.medical_treatment030232 urology & nephrologyUrologyCystectomyResection03 medical and health sciences0302 clinical medicineDiabetes mellitusHigh gradeAdjuvants ImmunologicUrethraRecurrenceDiabetes mellitusmedicineHumansIn patientNeoplasm InvasivenessAgedNeoplasm StagingRetrospective StudiesBladder cancerProgressionbusiness.industryHigh riskBladder cancerType 2 Diabetes MellitusMiddle Agedmedicine.diseasePrognosisComorbidityProgression-Free Survival3. Good healthBladder cancer; Diabetes mellitus; High grade; High risk; Progression; RecurrenceSettore MED/24OncologyDiabetes Mellitus Type 2Urinary Bladder NeoplasmsChemotherapy Adjuvant030220 oncology & carcinogenesisCohortBCG VaccineFemaleNeoplasm GradingbusinessAdjuvantUrologic oncology
researchProduct